Joe Laning

Joe Laning

Southborough, Massachusetts, United States
573 followers 500+ connections

About

SCIENTIFIC LEADER IN PRODUCT DEVELOPMENT AND CELL THERAPEUTICS MANUFACTURING
A highly…

Activity

573 followers

See all activities

Experience

  • Astellas Pharma US

    Westborough, Massachusetts, United States

Education

Publications

  • An Introduction to Cellular Reprogramming: The Plasticity of Cell Fates and Identities

    Chemical Biology in Regenerative Medicine: Bridging Stem Cells and Future Therapies (Chapter 8, pp.103-140). Sussex, UK: Wily and Sons.

    Other authors
  • Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ null (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.

    Clin Exp Immunol 174(3):372-88

    Other authors
    • Michael Brehm
    • Leonard Shultz
    • Laurence Covassin
  • Parameters for Establishing Humanized Mouse Models to Study Human Immunity: Analysis of Human Hematopoietic Stem Cell Engraftment in Three Immunodeficient Strains of Mice Bearing the IL2rnull Mutation

    Clin. Immunol. 2010, 135(1):84.

    Other authors
    • Michael Brehm
    • Amy Cuthbert
    • Aldo Rossini
    • Leonard Shultz
    • Dale Greiner
  • Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions

    Eur J Haematol. 2009. 82(2):124

    Other authors
  • Ex Vivo Expanded CD34+ Human Umbilical Cord Blood Cells Generate Multiple Lymphohematopoietic Lineages in NOD-scid IL2r null Mice.

    Exp. Biology and Med. 2008. 233(8):997.

    Other authors
    • Lisa Giassi
    • Leonard Shultz
    • Morey Kraus
    • Dale Greiner
  • In Vitro Analysis of CD40-CD154 and CD28-CD80/86 Interactions in the Primary T-Cell Response To Allogeneic ‘Nonprofessional’ Antigen Presenting Cells

    Transplantation. 2001. 71:1467.

    Other authors

Patents

  • System for Immunotherapy Targeting Tumor Propagation and Progression

    Issued US US009977025B2

    Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the…

    Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin

    Other inventors
    See patent

Recommendations received

View Joe’s full profile

  • See who you know in common
  • Get introduced
  • Contact Joe directly
Join to view full profile

Other similar profiles

Explore top content on LinkedIn

Find curated posts and insights for relevant topics all in one place.

View top content

Others named Joe Laning in United States

Add new skills with these courses